

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9806240-9

IPCS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/44, 31/55	A1	(11) International Publication Number: WO 97/48396 (43) International Publication Date: 24 December 1997 (24.12.97)
(21) International Application Number: PCT/AU97/00384 (22) International Filing Date: 18 June 1997 (18.06.97) (30) Priority Data: 08/667,147 20 June 1996 (20.06.96) US (71) Applicant (for all designated States except US): PHARMACY & THERAPEUTIC ADVISORY CONSULTANCY LTD. [-/GB]; 253 Gray's Inn Road, London WC1X 8QT (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): McLEAN, Allan Joseph [AU/AU]; 112 Munro Street, South Melbourne, VIC 3205 (AU). (74) Agent: PHILLIPS ORMONDE & FITZPATRICK; 367 Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, <u>SG</u> , SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: A METHOD OF TREATING LIVER DISEASE AND LIKE INDICATIONS WITH VASODILATING AGENTS (57) Abstract A method for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic and medicamentary liver damage, a liver parenchymic disorder or hepatitis, which method includes administering to a human or animal subject in need thereof a therapeutically active or prophylactically effective low dose amount of a vasodilating agent which selectively increases the supply of oxygenated blood to the liver by increasing hepatic arterial inflow. In one aspect of the invention the effective low dose amount of the vasodilating agent administered reduced with increases in severity of the disease state being treated.		